Agenus Inc. (AGEN) vs Relmada Therapeutics, Inc. (RLMD)
A side-by-side comparison of Agenus Inc. and Relmada Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AGEN
Agenus Inc.
$7.85HealthcareDelayed quote: Oct 6, 2026, 1:20 PM EDT
RLMD
Relmada Therapeutics, Inc.
$3.32HealthcareDelayed quote: Oct 6, 2026, 1:14 PM EDT
Total return — AGEN vs RLMD
growth of $100 · dividends reinvested · last 10yAGEN -94.1% (-24.6%/yr)RLMD +200.0% (+11.6%/yr)RLMD compounded faster over this window
Log scale — wide-divergence pair
AGEN RLMD
AGEN vs RLMD: by the numbers
- •RLMD is the larger company ($348M vs $327M market cap).
- •AGEN is profitable (69.34% net margin) while RLMD runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | AGEN | RLMD |
|---|---|---|
| P/E ratio | 2.97 | N/A |
| Forward P/E | 29.33 | N/A |
| P/S ratio | 2.46 | N/A |
| P/B ratio | N/A | 1.69 |
| EV / EBITDA | 8.52 | N/A |
Profitability
| Metric | AGEN | RLMD |
|---|---|---|
| Gross margin | 29.63% | 0.00% |
| Operating margin | -18.00% | 0.00% |
| Net margin | 69.34% | 0.00% |
| ROE | N/A | -29.98% |
| ROIC | N/A | -30.78% |
Growth (annualized)
| Metric | AGEN | RLMD |
|---|---|---|
| Revenue CAGR (5Y) | 14.13% | N/A |
| Total return CAGR (5Y) | -40.10% | -7.68% |
Frequently asked
- Is AGEN or RLMD more profitable?
- AGEN runs the higher net margin — AGEN at 69.34% versus RLMD at 0.00%.
- How have AGEN and RLMD total returns compared?
- Over the past 10 years, AGEN delivered -24.61% and RLMD delivered 12.41% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Agenus P/E ratioAgenus ROERelmada Therapeutics ROEAgenus operating marginRelmada Therapeutics operating marginAgenus revenue growthRelmada Therapeutics revenue growthAgenus free cash flowRelmada Therapeutics free cash flow
Agenus & Relmada Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.